Price Chart

Profile

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
URL https://www.sagerx.com
Investor Relations URL https://investor.sagerx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 02, 2024 (est.)
Last Earnings Release Feb. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
URL https://www.sagerx.com
Investor Relations URL https://investor.sagerx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release May. 02, 2024 (est.)
Last Earnings Release Feb. 14, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A